WHO calls on public for ideas to rename monkeypox
‘Poxy McPoxface’, ‘TRUMP-22’, and ‘Mpox’ are just some of the suggestions submitted by the public
The World Health Organisation (WHO) is asking for the public’s help in renaming the monkeypox virus due to concerns over misconceptions associated with the current name.
Disease names are often chosen behind closed doors by a technical committee, but the WHO has this time decided to open up the process to the public.
There have been recent calls for the disease to be renamed, with critics calling it misleading since monkeys are not the original animal host. In June, a group of scientists wrote a position paper calling for a name that was ‘neutral, non-discriminatory and non-stigmatizing'.
‘It's very important we find a new name for monkeypox because this is best practice not to create any offence to an ethical group, a region, a country, an animal etc,’ WHO spokesperson Fadela Chaib said on Tuesday.
So far, dozens of suggestions have been submitted through the WHO’s online portal. These range from technical (OPOXID-22), to political (TRUMP-22), to light-hearted (Poxy McPoxface). One of the more popular submissions so far is Mpox, submitted by Samuel Miriello, the director of a men's health organisation in Canada.
After convening a group of global experts on August 8, the WHO also decided to rename the two dominant variants of monkeypox. Previously called the Central African or Congo Basin clade and the West African clade, the strains will now be officially called Clade I and Clade II, respectively. The group also decided that Clade II consists of two distinct subclades.
The WHO said it would decide between the proposals based on ‘their scientific validity, their acceptability, their pronounceability (and) whether they can be used in different languages’.
Monkeypox is a viral infection that spreads through close contact and can be identified by flu-like symptoms, distinctive rashes and lesions on the skin. The World Health Organisation (WHO) designated the outbreak as a public health emergency of international concern in late July after cases of the disease were recorded in more than 80 countries where it is not usually found.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News From Pharma to Table? Direct-to-consumer pharma sales and price cuts ramp up in US
The pharmaceutical industry is witnessing a seismic shift as major companies embrace direct-to-consumer sales models and announce significant price reductions across the United States, responding to mounting pressure from the Trump administration to ta... -
News A Day in the Life of a Director of Business Development
In this Day in the Life of interview, Thomas Hauser, Director of Business Development at Tjoapack. Thomas has spent nearly 30 years in the pharmaceutical industry and describes how he still finds curiosity and excitement in the bigger picture of global... -
News Women in Pharma: Our hopes for 2025 and beyond
Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the... -
News CPHI Milan 2024 - From the Floor
Milan and CPHI welcome you to 2024 CPHI Milan! As we celebrate the 35th edition of our flagship CPHI show, editors Vivian Xie and Lucy Chard bring you the latest from the show floor, conference sessions, and innovative solutions from all exhibitors, at... -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News A Day in the Life of a Global CDMO Chapter Lead – Manufacturing
The 'Day in the Life of' series has covered many aspects of the pharmaceutical pipeline, including R&D and procurement, now we're taking a look at manufacturing from a global CDMO perspective.